Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | PTPRB | P23467 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30415301 | 1.00 | TRPA1 (0.40) | TRPA1PTPRBSYKCTSSCTSK | |
| SCHEMBL21381413 | 0.81 | CTSA (0.43) | MAPK1ALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL28311959 | 0.79 | TRPA1 (0.55) | TRPA1MAPK1ALDH1A1AAK1MAPT | |
| SCHEMBL21391999 | 0.78 | CTPS1 (0.53) | PTPRB | |
| SCHEMBL30416278 | 0.78 | CTPS1 (0.53) | PTPRB | |
| SCHEMBL1811481 | 0.76 | LMNA (0.57) | TRPA1STK17BSTK17AMAPKAPK2LMNA | |
| SCHEMBL27287525 | 0.74 | KMT2A (0.46) | TRPA1MAPK1AAK1STK17BSTK17A | |
| SCHEMBL21392096 | 0.74 | LMNA (0.52) | TRPA1SYKMAPK1ALDH1A1STK17B | |
| SCHEMBL29168235 | 0.74 | ALDH1A1 (0.40) | PTPRBSYKCTSSCTSKMAPK1 | |
| SCHEMBL30133703 | 0.74 | ALDH1A1 (0.40) | PTPRBSYKCTSSCTSKMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868051-B | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| CN-111868051-A | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | TRPA1 780/4885PTPRB 4561/4885SYK 4324/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | TRPA1 780/4885PTPRB 4561/4885SYK 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.